The SANOVO data de-risk the Tagrisso+Orpathys first-line regulatory path in China and strengthen the overall Tagrisso franchise against emerging EGFR-TKI competition. Traders should watch for regulatory submission timelines in China and potential global filings; the SAFFRON global readout in the post-Tagrisso setting further supports the combination's broad utility. Near-term catalyst is data presentation at a medical meeting.
Drugs in focus
AZN drug pipeline →ORPATHYS
◆ Mixed Named in this 6-K- Impact
- Phase
- Approved in China (3 indications); global Phase 3 readout pending
- Time to market
- Already approved and marketed in China (lung cancer since 2021, gastric cancer July 2026). Ex-China (US/EU) approval is not filed yet — timing hinges on the SAFFRON global Phase 3 readout expected H2 2026.
- Next catalyst
- None dated
What to watchWatch for SAFFRON/SANOVO Phase 3 topline data in H2 2026, a positive readout supports global (ex-China) filings for savolitinib and would be the biggest near-term share-price lever; a miss or delay would hit a stock already near its 52-week low ($11.13 vs $18.30 high). HUTCHMED carries $1.37B cash, so the stock isn't a financing story, but this one drug's readout is the dominant H2 catalyst alongside sovleplenib NDA decisions.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Sep 1 $162.47entry
- T+1 · 3mo ago −0.52%α −0.96% · $161.63
- T+5 · 2mo ago −3.40%α −3.49% · $156.94
- T+20 · 7w ago +0.47%α −0.71% · $163.23
- T+53 · todayOpen
- T+60 · in 8d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
AstraZeneca announced positive Phase III SANOVO trial results showing Tagrisso plus Orpathys achieved a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) versus Tagrisso alone in first-line MET-overexpressing EGFR-mutated NSCLC. The combination also showed encouraging overall survival benefit. These data extend the all-oral combination into the first-line setting, reinforcing Tagrisso's backbone role and supporting regulatory submissions in China.
Key Facts
- SANOVO Phase III trial met primary endpoint: statistically significant and highly clinically meaningful PFS improvement for Tagrisso + Orpathys vs Tagrisso alone in 1L EGFRm MET-overexpressing NSCLC.
- PFS benefit demonstrated in both high MET (IHC 3+) and ITT (IHC 2+, IHC 3+) populations.
- Overall survival, a secondary endpoint, showed very encouraging clinical benefit; trial continuing follow-up.
- Safety profile consistent with known profiles of each medicine; no new safety findings.
- Data will be presented at a forthcoming medical meeting and shared with regulatory authorities.
- Combination already approved in China for post-EGFR-TKI MET-amplified patients (SACHI trial) and recently reported positive SAFFRON global Phase III results in post-Tagrisso setting.
- Orpathys is jointly developed by AstraZeneca and HUTCHMED, commercialized by AstraZeneca.
Financial Impact
Positive Phase III data in 1L EGFRm NSCLC with MET overexpression expands addressable patient population for Tagrisso + Orpathys combination; Tagrisso is a multi-billion-dollar franchise and this label extension supports revenue durability against competitive pressure.
Risk Factors
- Regulatory approval in China is not guaranteed; SANOVO is a China-only trial and may require additional global data for ex-China filings.
- Competitive landscape includes other EGFR-MET bispecific antibodies and combination approaches that could limit market share.
- Overall survival data are still immature; final OS readout could alter the risk/benefit profile.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-007983 |
| Document: 0001654954-26-007983-index-headers.html | 0001654954-26-007983 |
| Document: 0001654954-26-007983-index.html | 0001654954-26-007983 |
| Document: 0001654954-26-007983.txt | 0001654954-26-007983 |
Track record
77 reports on AZN
19 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 28 of 37 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.45 −0.59% settles Nov 23
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.45 −0.46% settles Nov 23
- Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.45 −0.35% settles Nov 23
- Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.45 −1.28% ▼ −1.32% −4.61% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.45 −1.14% ▲ +1.51% +1.43% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.45 −1.14% ▲ +1.51% +1.43% vs SPY
- Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.45 −1.18% ▼ −0.12% +2.59% vs SPY
- Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.45 +8.45% ▲ +8.11% +10.10% vs SPY
- Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.45 +6.88% ▲ +0.51% −0.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers